Jianhui Ma

Jianhui Ma

Auto-generated profile, based on publicly available information

Jianhui Ma

Zentalis Pharmaceuticals

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
NJNathan M. Jameson
Nathan M. Jameson
JMJianhui Ma
Jianhui Ma
JBJorge Benitez
Jorge Benitez
AIAlejandro Izurieta
Alejandro Izurieta
JHJee Yun Han
Jee Yun Han
FFFrank Furnari
Frank Furnari
The epidermal growth factor receptor (EGFR) is overexpressed in numerous solid tumors and is the subject of extensive therapeutic efforts. Much of the research on EGFR is focused on protein dynamics and downstream signaling; however, few studies have explored its transcriptional regulation. Here, we identified two enhancers (CE1 and CE2) present within the first intron of the EGFR gene in models of glioblastoma (GBM) and head and neck squamous cell carcinoma (HNSCC). CE1 and CE2 contain open chromatin and H3K27Ac histone marks, enhance transcription in reporter assays, and interact with the EGFR promoter. Enhancer genetic deletion by CRISPR/Cas9 significantly reduces EGFR transcript levels, with double deletion exercising an additive effect. Targeted repression of CE1 and CE2 by dCas9-KRAB demonstrates repression of transcription similar to that of genomic deletion. We identify AP-1 transcription factor family members in concert with BET bromodomain proteins as modulators of CE1 and CE2 activity in HNSCC and GBM through de novo motif identification and validate their presence. Genetic inhibition of AP-1 or pharmacologic disruption of BET/AP-1 binding results in downregulated EGFR protein and transcript levels, confirming a role for these factors in CE1 and CE2. Our results identify and characterize these novel enhancers, shedding light on the role that epigenetic mechanisms play in regulating EGFR transcription in EGFR-dependent cancers. Implications: We identify critical constituent enhancers present in the first intron of the EGFR gene, and provide a rationale for therapeutic targeting of EGFR intron 1 enhancers through perturbation of AP-1 and BET in EGFR-positive malignancies.

4 January 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
DKDaehwan Kim
Daehwan Kim
HCHeekyung Chung
Heekyung Chung
WLWen Liu
Wen Liu
KJKangjin Jeong
Kangjin Jeong
TOTugba Y. Ozmen
Tugba Y. Ozmen
MLMark R. Lackner
Mark R. Lackner
Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating multiple cell cycle checkpoints. Here we characterized the relationship between Cyclin E1/CDK2 activation and sensitivity to the selective WEE1 inhibitor azenosertib. We found that ovarian cancer cell lines with high levels of endogenous Cyclin E1 expression or forced overexpression were exquisitely sensitive to azenosertib and these results extended to in vivo models of ovarian and uterine serous carcinoma. Models with high Cyclin E1 expression showed higher baseline levels of replication stress and enhanced cellular responses to azenosertib treatment. We found azenosertib synergized with different classes of chemotherapy and described distinct underlying mechanisms. Finally, we provided early evidence from an ongoing phase I study demonstrating the clinical activity of monotherapy azenosertib in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas.

5 May 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progression, including activation of WEE1-dependent cell cycle checkpoints. If DNA damage occurs during replication, the WEE1 checkpoint is activated, thereby preventing the progression of the cell cycle. This allows damaged DNA to be repaired before cells enter mitosis, or if the damage is too extensive, induction of apoptosis. These observations have made WEE1 a promising anticancer therapeutic target. Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor. The antiproliferative activity of azenosertib on cancer cell lines is consistent with a WEE1-dependent mechanism of action exemplified by reduction of pY15-CDK1 levels and increases in DNA damage markers. Azenosertib further exacerbates the effect of replicative stress and DNA damage by allowing cancer cells to prematurely enter mitosis, leading to mitotic catastrophe and apoptosis. Azenosertib has optimized pharmacokinetic and pharmacodynamic properties, yielding robust tumor growth inhibition in a broad range of tumor models, and is highly effective at delaying the duration of tumor regrowth after cessation of treatment. We have explored various dosing schedules in preclinical efficacy models for azenosertib that preserve antitumor activity with minimal toxicity. Phase I studies with azenosertib as monotherapy have shown preliminary clinical activity in patients with advanced solid tumors. The data presented herein support further studies of azenosertib monotherapy across multiple solid tumor indications.

1 February 2025 in Cancer Research Communications
Verified
Journal Article
Open access
NJNathan M. Jameson
Nathan M. Jameson
DKDaehwan Kim
Daehwan Kim
CLCatherine Lee
Catherine Lee
BSBlake Skrable
Blake Skrable
ASAlexandra Shea
Alexandra Shea
MLMark R. Lackner
Mark R. Lackner
Kirsten rat sarcoma (KRAS) is a potent oncogenic driver that results in the downstream hyperactivation of MAPK signaling while simultaneously increasing replication stress (RS) and accumulation of DNA damage. KRASG12C mutations are common and targetable alterations. Therapeutic inhibition of KRASG12C and eventual resistance to these inhibitors are also known to drive RS and DNA damage through adaptive mechanisms that maintain addiction to high MAPK signaling. High levels of RS result in a stronger reliance on cell-cycle checkpoints, thereby introducing a vulnerability to inhibition of cell-cycle checkpoint regulators such as the WEE1 kinase. This provides a rationale for combining azenosertib, a novel, selective, and orally bioavailable WEE1 inhibitor, with KRASG12C inhibitors. An in vitro combination of azenosertib with multiple KRASG12C inhibitors demonstrated synergistic cell growth inhibition across a panel of KRASG12C cell lines in both 2D and 3D assays. In vivo studies demonstrated that azenosertib exhibited significant monotherapy activity as well as synergistic tumor growth inhibition (TGI) when combined with KRASG12C inhibitors, including tumor regression in cell-derived xenograft models of non–small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Importantly, KRASG12C inhibitor–resistant cell-derived xenograft and patient-derived xenograft models demonstrated synergistic TGI in combination arms. Finally, analysis of biomarkers from in vitro and in vivo tumor samples displayed increases in protein markers of RS, DNA damage, and apoptosis after combination treatment. Taken together, our results suggest that the combination of azenosertib with KRASG12C inhibitors enhances TGI over single-agent therapy and may be an effective treatment strategy for patients with KRASG12C tumors. Significance: Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.

20 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GZGuobao Zhang
Guobao Zhang
PHPeter Q. Huang
Peter Q. Huang
KBKevin D. Bunker
Kevin D. Bunker
SHSayee G. Hegde
Sayee G. Hegde
JMJianhui Ma
Jianhui Ma
RKRamesh Kakarla
Ramesh Kakarla

14 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SHSayee G. Hegde
Sayee G. Hegde
PHPeter Q. Huang
Peter Q. Huang
KBKevin D. Bunker
Kevin D. Bunker
CHChad D. Hopkins
Chad D. Hopkins
DSDeborah H. Slee
Deborah H. Slee
ACAlex Chao
Alex Chao